Motavizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Motavizumab?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target RSV glycoprotein F
Clinical data
Trade names Numax
i.v.
Pharmacokinetic data
Protein binding None
Identifiers
677010-34-3 N
J06BB17
UNII 50Y163LK8Q YesY
KEGG D06621 YesY
Chemical data
Formula C6476H10014N1706O2008S48
Approximately 148 kDa
 N (what is this?)  (verify)

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.[1]

In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody Palivizumab.[2]

In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV.[3]

References[edit]

  1. ^ ClinicalTrials.gov
  2. ^ "FDA Panel Nixes Licensing Request for Motavizumab". Medscape. 3 June 2010. Retrieved 2014-03-02. 
  3. ^ "AstraZeneca halts work on Motavizumab drug". BBC News. 21 December 2010. Retrieved 2010-12-21. 

External links[edit]